Drug Interactions between ibandronate and Linzess
This report displays the potential drug interactions for the following 2 drugs:
- ibandronate
- Linzess (linaclotide)
Interactions between your drugs
No interactions were found between ibandronate and Linzess. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
ibandronate
A total of 178 drugs are known to interact with ibandronate.
- Ibandronate is in the drug class bisphosphonates.
- Ibandronate is used to treat the following conditions:
Linzess
A total of 59 drugs are known to interact with Linzess.
- Linzess is in the drug class guanylate cyclase-C agonists.
- Linzess is used to treat the following conditions:
Drug and food interactions
ibandronate food
Applies to: ibandronate
ADJUST DOSING INTERVAL: Food significantly decreases the bioavailability of oral ibandronate. The manufacturer reports up to a 75% decrease in bioavailability when administered 2 hours after a standard meal.
MANAGEMENT: Oral ibandronate should be administered on an empty stomach (after an overnight fast of at least 6 hours) with a 180 to 240 mL glass of plain water and no other food or drink should be taken for at least 30 minutes after administration.
References (3)
- (2005) "Product Information. Boniva (ibandronate)." Roche Laboratories
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
linaclotide food
Applies to: Linzess (linaclotide)
ADJUST DOSING INTERVAL: Administration of linaclotide in the fed condition resulted in more gastrointestinal side effects and more frequent and looser stools, than when it was administered under fasting conditions.
MANAGEMENT: It is recommended to take linaclotide 30 minutes before a meal.
References (2)
- EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid
- (2012) "Product Information. Linzess (linaclotide)." Forest Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.